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Background: The COVID-19 pandemic has led to an urgent requirement for novel
diagnostic tests that determine infection with SARS-CoV-2 and the development of an
immune response against it. The perspective of end users on the characteristics and
clinical use of these assays has not been previously considered.
Methods: We surveyed 17,186 health care professions (HCPs) in 29 countries to gauge
opinion on the design, use, diagnostic impact and diagnostic accuracy of COVID-19
tests. Results were correlated with national statistics on the burden of disease and testing
in individual countries.
Results: HCPs overwhelmingly recognized the importance of COVID-19 tests but
37.1% were unsure of the appropriate timing of investigations relative to disease
symptoms. Confidence in the diagnostic accuracy of assays varied inversely with
COVID-19-related mortality in individual countries but had no relationship with the total
number of tests performed. There was global consensus that the most important impact
of positive antigen and antibody testing was confidence in returning to work following
recovery. Saliva was the preferred sampling fluid for COVID-19 diagnostic tests in all
groups surveyed.
Conclusions: HCP input can ensure novel assays are fit for purpose in varied global
health care settings, but HCPs may require support to effectively use novel diagnostics
thus minimizing waste when supplies are limited.
Keywords: SARS-CoV-2, COVID-19, global health, PCR testing, serological testing
INTRODUCTION
As of January 2021, the coronavirus disease-19 (COVID-19) pandemic has resulted in over 93
million cases worldwide and over 2 million deaths (1). The pandemic has led to an urgent need
for novel diagnostic tests that determine infection and immunity to SARS-CoV-2 at an individual
and population level. Tests that directly confirm the presence of viral nucleic acids or proteins
are used to shape national and international statistics on case burden and fatality rates (2), enable
enrolment into clinical trials of therapeutics and supportive care and guide isolation policies for
public health benefit.
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While measurable, long-term correlates of immunological
protection against SARS-CoV-2 remain unclear (3), cross-
sectional sero-surveys have emerged as the favored tool in
estimating prior exposure to the virus or response to vaccination
and, by inference, the background herd immunity present at a
population level. Early data suggests the presence of antibodies
affords protection against viral re-infection (4). Ultimately,
estimates of herd immunity will influence the stringency of
local, national and international measures aimed at containing
the spread of the virus. By extension, considerable controversy
surrounds the concept of “immunological passports” that might
facilitate individual relaxation of such measures (5).
The determinants of the quality and impact of diagnostic
testing are multi-factorial and essential to understand in order
to improve global health outcomes (6). At the level of the
test itself, performance characteristics including the analytical
sensitivity and specificity must be considered alongside the
clinical pre-test probability. Tests detecting viral nucleic acids or
proteins are time-dependent, displaying the greatest sensitivity
and diagnostic utility shortly after symptom onset. Polymerase
chain reaction (PCR) testing remains the gold standard method
of case definition (2); the sensitivity of PCR tests depends on
the type of body fluid analyzed (7) and time from symptom
onset (8, 9). Rapid antigen tests have been deployed in
asymptomatic screening programmes in an attempt to interrupt
viral transmission (10, 11). These tests appear less sensitive that
PCR but may be helpful in detecting individuals with relatively
high-viral loads (PCR cycle thresholds <30) and guiding self-
isolation policy (12, 13).
In contrast, antibody responses to viral infections take time
to develop and antibody tests are only reliably sensitive two
weeks after symptom onset (14, 15). Over 90% of PCR positive
individuals mount a detectable antibody response following
infection if a sufficiently sensitive assay is used for detection (16),
but concern has been raised regarding the real-life performance
of first-generation point lateral flow tests (17). Nevertheless,
serological investigations may provide a helpful adjunct to
acute molecular diagnostics, enhancing overall case detection,
particularly in individuals testing negative by PCR (16, 18).
Arguably the most important factor determining the impact
of COVID-19 laboratory diagnostics is understanding how
health care professionals (HCPs), organizations, governments
and individuals will use and interpret the results of such tests.
There may be regional variation in these factors depending on
access to diagnostics and disease burden.
Little attention has been paid to these concepts, or how
diagnostics might be deployed in resource-limited settings where
the capacity for testing is limited (19). To enable the design
and implementation of future diagnostics, in collaboration with
M3 Global Research, we sought the opinion of health care
professionals from around the world.
METHODS
To understand health care professionals’ (HCPs) opinions on
COVID-19 diagnostic tests, we undertook an international study
supported by the healthcare research company M3 Global
Research. A short survey was devised (provided in full in the
Supplementary Methods) and sent to approximately 100,000
participants. Participants were a random sample of HCPs from
M3 Global Research and their global partners’ existing databases.
Participants were invited to participate in a 10min online study
by email. The survey was distributed in English and the local
languages with the exception of India and the Nordic countries
who received the English version only. There was no incentive
for taking part and the study sponsors were not mentioned.
All respondents had previously opted in to receiving email
invitations to online surveys. No follow-up or reminder emails
were sent. The invitation clearly stated the aims and objectives of
the study, the estimated length of interview, and that there was
no incentive available for their participation, other than a copy of
the report if requested. The research sponsor was not mentioned.
All responses were pseudonymised so no respondents were
identifiable, and no personal data was shared. The M3
Global Research privacy policy (https://www.m3globalresearch.
com/research/privacy/) outlines how respondents’ data will be
processed, and participants can withdraw their consent to take
part at any time during the process. Ethical approval for this
study and written informed consent from the participants of the
study were not required in accordance with local legislation and
national guidelines.
Responses were collated by M3 Global Research and analyzed
by the University of Birmingham. A total of 17,186 responses
were received between 16th and 23rd April 2020. The overall
response rate to the survey was similar to that of other M3
Global Research projects. The primary medical specialism of
respondents is provided in Supplementary Table 1. At the time
the survey was distributed, “antigen test” was the commonly
used, albeit scientifically imprecise, term encompassing a variety
of tests used to confirm acute SARS-CoV-2 infection including
polymerase chain reaction and direct viral antigen detection.
Data on the global burden was extracted from public datasets
collated by Our World in Data and available at https://github.
com/owid/covid-19-data/tree/master/public/data and accessed
on 23/4/2020. Confirmed cases and deaths were originally
derived from the European Center for Disease Prevention and
Control statistics. High IncomeCountries (HIC) and LowMiddle
Income Countries (LMIC) were defined by the Organization for
Economic Co-operation and Development.
Data were analyzed using Graph Pad Prism 8.4.2 for macOS.
Significant trends in ordinal survey data were analyzed using the
Chi squared test for trend. World map figures were produced
using Map Chart (https://mapchart.net/world.html).
RESULTS
A total of 17,186 responses were received from 21 high income
countries (HICs) and 8 low-middle income countries (LMICs)
(Table 1). Respondents from high-income countries accounted
for 82.8% of all respondents. 53.0% of respondents stated they
worked in secondary care, 12.9% in primary care and 34.1% did
not specify their specialism or place of work.
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TABLE 1 | Demographics of health care professionals participating in this study, the reported COVID-19 burden of disease and the total number of antigen tests











Argentina 128 17.2 74.2 8.6 0.8 0.3
Australia 847 25.7 32.5 41.8 17.32 0.3
Austria 78 19.2 59.0 21.8 21.52 5.3
Belgium 130 13.8 52.3 33.8 14.27 51.6
Brazil 450 7.8 60.2 32.0 n.d. 1.3
Canada 366 21.3 44.3 34.4 15.05 4.9
China 609 1.3 58.8 39.9 n.d. 0.3
Colombia 180 43.3 52.2 4.4 1.22 0.4
Denmark 67 19.4 47.8 32.8 17.34 6.4
Finland 43 14.0 67.4 18.6 11.01 2.5
France 1001 12.8 34.5 52.7 7.05 31.6
Germany 575 10.4 50.8 38.8 20.94 5.9
India 797 21.8 56.2 22.0 0.32 0.0
Italy 1515 6.6 58.4 35.0 24.52 1.1
Japan 2046 10.6 71.5 17.9 0.98 0.1
Mexico 291 34.0 56.4 9.6 0.3 0.7
Netherlands 115 17.4 42.6 40.0 10.19 22.8
New Zealand 30 30.0 33.3 36.7 18.52 0.3
Norway 31 16.1 41.9 41.9 26.66 3.0
Poland 29 6.9 86.2 6.9 5.65 1.1
Russia 240 9.2 77.9 12.9 14.9 0.3
South Africa 167 9.0 24.0 67.1 2.16 0.1
South Korea 904 19.1 72.9 8.0 11.09 0.5
Spain 1035 15.1 52.2 32.8 20.02 45.8
Sweden 80 28.8 68.8 2.5 9.35 17.4
Switzerland 90 13.3 51.1 35.6 26.25 13.7
Turkey 334 21.0 68.3 10.8 8.51 2.7
United Kingdom 826 13.4 38.0 48.5 5.91 25.8
United States 4182 8.0 45.7 46.3 12.08 13.6
Total 17186 12.9 53.0 34.1
*Data on COVID-19 testing and deaths sourced from ourworldindata.org, accessed 24/4/2020. n.d, no data available.
The overwhelming majority of respondents considered
antigen tests critically important (63.3%) or very important
(27.1%) in the control of the COVID-19 pandemic (Figure 1A).
By comparison, fewer respondents considered antibody tests
important for the control of the pandemic (critically important
44.0% or very important 34.9%, χ2 = 1513, df =3, p <
0.0001). LMICs attributed greater importance to antigen tests
in the control of the pandemic than HICs (χ2 = 201.8, df
= 3, p < 0.0001), while a greater percentage of respondents
from HICs considered antibody tests of critical importance in
pandemic control (χ2 = 228.9, df =3, p < 0.0001). Accordingly,
the likelihood of respondents requesting antigen tests was
significantly greater than that for an antibody tests overall (χ2 =
510.5, df =4, p < 0.0001, for trend); this effect was more marked
when LMICs were compared to HICs (Figure 1B).
Despite respondents acknowledging the importance of
antigen and antibody tests for COVID-19 and stating they
would request these investigations, 37.1% of respondents
were somewhat unsure or completely unsure regarding the
appropriate timing of diagnostic testing with respect to the
disease course. Uncertainty in the appropriate timing of testing
was marginally greater amongst those working in secondary care
(35.6%) than primary care (32.7%). Overall confidence in the
timing of testing was significantly greater in LMICs compared to
HICs (χ2 = 621.4, df =3, p < 0.0001) (Figure 1C). We found
no linear relationship between the total number of tests per
capita performed in different countries and the confidence of
health care professionals in those countries in requesting tests.
Considerably less testing has taken place in LMICs compared to
HICs (Table 1).
Participants were asked at what stage of the disease they
considered antigen and antibody tests to be most accurate
(Figure 2A): despite a lack of self-reported confidence in the
appropriate timing of COVID-19 diagnostics, 90.3% and 89.6%
of respondents recognized antigen and antibody tests to be most
accurate at appropriate stages of disease course (i.e., antigen
tests before symptoms are present and during the early stages of
symptoms, antibody tests as the patient recovers from their illness
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FIGURE 1 | (A) Health care professionals’ perceptions of the importance of antigen and antibody based diagnostics in controlling the COVID-19 pandemic. (B)
Self-reported likelihood of health care professionals requesting antigen and antibody based diagnostic tests for COVID-19 disease. (C) Overall self-reported
confidence of health care professionals in requesting COVID-19 diagnostic tests.
and after the patient has recovered from COVID-19). There was
little difference between respondents in primary and secondary
care with respect to the percentage of respondents who failed
to recognize the appropriate timing of antigen tests (primary
care 8.7% vs. secondary care 8.5% vs. no response 12.0%).
There was no relationship between the self-reported confidence
of respondents in the timing of COVID-19 diagnostics and
knowledge of when antigen and antibody tests would be most
accurate. A negative correlation was noted between the number
of COVID-19 antigen tests requested per capita in individual
countries, and the percentage of respondents who considered
antigen tests to be most accurate outside of the pre-symptomatic
or symptomatic phase of these disease (ρ = −0.4508, CI
−0.7093–0.0854, p = 0.02). A similar relationship for antibody
tests was not observed.
Given the global increase in antigen testing for COVID-19,
and the uncertainty expressed by HCPs on when to request
diagnostic investigations, we went on to consider the potential
burden of sub-optimally requested COVID-19 antigen tests
globally. Assuming, health care professionals who did not know
when to optimally request an antigen test would still request such
investigations and based on national testing figures, the potential
global impact of this pre-analytical error may have exceeded
1,000,000 tests by April 2020 (Figure 2B).
There was no consensus from respondents on whether a
COVID-19 assay should be optimized for sensitivity, specificity
or whether both are equally important. For antigen tests, a
small majority (41.3%), expressed the opinion both sensitivity
and specificity were equally important, however opinion was
more polarized in LMICs compared to HICs (Figure 3A). A
slight overall preference for optimisation toward test sensitivity
was noted for antibody tests (38.5%). A significantly greater
proportion of respondents favored laboratory testing over home
testing methods in LMICs compared to HICs (57.5% vs., 50.1%,
χ
2
= 54.42, df =1, p < 0.0001) however there is clearly demand
for both modalities of test delivery (Figure 3B). Saliva was the
preferred sampling fluid for COVID-19 testing in HICs and
LMICs, and primary and secondary care (Figure 3C).
We noted marked international variability in the confidence
of respondents in the accuracy of the COVID-19 diagnostic tests
currently available to them (Figure 4A). With the exception of
Japan, whose self-reported confidence in requesting diagnostic
tests and confidence in the diagnostic accuracy of tests were both
2.5 standard deviation away from the mean of all HICs, a trend
seen in other M3 surveys, we identified a negative correlation
between confidence in the diagnostic accuracy of the tests and
the number of deaths per capita documented in each country (ρ
=−0.4944, CI−0.7400–−0.1324, p= 0.0102) (Figure 4B).
There was global consensus on the impacts of positive antigen
and antibody tests on individuals; confidence in returning
to work was considered the most important impact of a
positive antigen and antibody test, followed by confidence
in interacting with family and friends, outside of work
(Figures 5A,B). Reducing concern around personal protective
equipment and hand-washing were considered least important.
Minimal geographic variation was observed with respect to these
patterns (Figure 5C and Supplementary Figures 1, 2). There
was high concordance between the perceived impact of positive
antigen and antibody tests in respondents from individual
countries (Supplementary Figure 3).
DISCUSSION
Understanding the opinion and behaviors of HCPs who use
COVID-19 diagnostics is critical in maximizing the utility and
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FIGURE 2 | (A) Health care professionals’ opinion on when antigen and antibody tests will demonstrate maximum accuracy in the assessment of COVID-19 relative
to disease stage. (B) Total number of potentially sub-optimally requested COVID-19 tests requested per country based on national testing statistics.
impact of each diagnostic test, particularly when access to
diagnostic reagents and platforms is limited (20–22). Molecular
testing is now an established measure in controlling the COVID-
19 pandemic and their widespread use is reflected in the high
likelihood of health care professionals requesting antigen testing
seen in our data. Our survey was distributed in late April 2020,
following the peak of the first wave of the pandemic in many
countries. It is, therefore, concerning that as many as 9.7% of
HCP approached did not understand the appropriate timing of
antigen testing with respect to symptom onset.
Furthermore, we observed marked regional differences in
health care professionals’ confidence in the diagnostic accuracy
of antigen tests. The causes of these differences are unclear: there
was no relationship between the total number of tests ordered
per capita and confidence in diagnostic accuracy of the tests.
However, the negative correlation between confidence in the
diagnostic accuracy of the tests and the number of deaths per
capita documented in each country may provide insight into the
known limitations of testing and be important in understanding
health care professionals’ behavior in test interpretation during
the evolving pandemic. These observations merit further
investigation, in particular, how the potential strengths and
limitations of novel diagnostic tests for infectious diseases are
communicated to health care professions, organizations and
governments during rapidly evolving public health emergencies.
In resource limited settings, is critical that every test
undertaken has maximum impact on the diagnostic or public
health containment process. 37.1% of respondents in this survey
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FIGURE 3 | (A) Health care professionals’ preferences for performance characteristics of COVID-19 antigen and antibody tests. (B) Health care professionals’
preference for laboratory vs. home testing services for COVID-19 diagnostics. (C) Health care professionals’ preference for sample used in COVID-19 diagnostic test.
FIGURE 4 | (A) Relative confidence of health care professionals in the diagnostic accuracy of currently available COVID- 19 tests per country (5 = high confidence, 1
= low confidence). (B) Relationship between health care professionals confidence in diagnostic accuracy of COVID-19 tests and the number of COVID-19 deaths per
100,000 population in respondents countries.
were somewhat unsure or completely unsure as to what test
should be undertaken in different stages of COVID-19 disease,
yet 79.6 and 78.0% were likely to request antigen and antibody
testing respectively. As the number of tests increased per
capita, respondents were less likely to express the opinion that
these tests were most accurate during the pre-symptomatic or
symptomatic phase of the disease. This may reflect a lack of
knowledge, or a diversification in what antigen tests are used
for in these countries, for example screening. Given the rapid
increase in COVID-19 testing, the impact on public health, health
inequalities, and health economics of sub-optimally requested
COVID-19 investigations also requires urgent attention.
Our data documents the varied perspectives of health care
professionals on what types of test and what samples are
most desirable with respect to COVID-19 diagnostic assays.
Laboratory based testing was favored in primary care, secondary
care and in LMICs and there was a preference for saliva as the
sampling fluid of choice in respondents from all demographics.
Saliva has shown superior performance to nasopharyngeal swabs
for antigen testing for SARS-CoV-2 and is simple and non-
invasive (23). Antibodies against bacteria and viruses can already
be routinely detected in saliva with levels correlating to serum
concentrations (24, 25). When translated into point of care
lateral flow test (similar to a pregnancy test), the presence or
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FIGURE 5 | Health care professionals assessment of the impact of a positive antigen (A) or antibody test (B) on an individual level; heat maps are scaled by the total
number of countries ranking each parameter by importance. (C) Differences in the assessment of the impact of positive COVID-19 antigen and antibody tests
displayed by country; heat maps are scaled using the mean score for each parameter provided by respondents from individual countries.
absence of biomarkers of infection can be ascertained with
no invasive sampling or further laboratory equipment, with
implications for deployment in resource-limited settings. These
findings should prompt assay development by academia and
industry in collaborationwith the end users and acknowledgment
that a single test or platform might not be suitable for
all applications.
In conclusion, the rapid global growth in the use of diagnostic
assays for COVID-19 is an impressive achievement that has
required the collaboration of multiple stakeholders including
governments, industry and academia. Health care professionals,
the end users of these novel assays, can provide invaluable
insight into their diagnostic impact and help guide future assay
development for different global settings.
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